← 產業報告目錄
Regulatory T-Cell (Tregs) Therapies Market Size, Share & Trends Analysis Report Therapeutic Area (Autoimmune Disorders, Oncological Disorders, Post-Transplant Infection, Neurological Disorders, Metabolic Disorders, Dermatological Disorders), by Products (Tregs, Interleukin 2, Monoclonal Antibodies, Small Molecules, CAR-Treg, Other Products), by Source of T-Cells (Autologous, Allogeneic), By Region, And By Segment Forecasts, 2026-2035
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-04頁數 160報告編號 INSIGHTACE-211a66d082
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2026 to 2035 projection horizon, the worldwide Regulatory T-Cell (Tregs) Therapies Market is projected to register a CAGR of 40.0%.
Regulatory T-Cell (Tregs) Therapies encompasses They are vital in preventing and controlling excessive immune responses and autoimmunity. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is fueled by expanding requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, fueled by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Regulatory T-Cell (Tregs) Therapies Market Snapshot
Chapter 4. Global Regulatory T-Cell (Tregs) Therapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Therapeutic Area Estimates & Trend Analysis
5.1. By Therapeutic Area & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2035 for the following By Therapeutic Area:
5.2.1. Autoimmune Disorders
5.2.2. Oncological Disorders
5.2.3. Post-Transplant Infection
5.2.4. Neurological Disorders
5.2.5. Metabolic Disorders
5.2.6. Dermatological Disorders
Chapter 6. Market Segmentation 2: By Products Estimates & Trend Analysis
6.1. By Products & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2035 for the following By Products:
6.2.1. Tregs
6.2.2. Interleukin 2
6.2.3. Monoclonal Antibodies
6.2.4. Small Molecules
6.2.5. CAR-Treg
6.2.6. Other Products
Chapter 7. Market Segmentation 3: By Source of T-Cells Estimates & Trend Analysis
7.1. By Source of T-Cells & Market Share, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2035 for the following By Source of T-Cells:
7.2.1. Autologous
7.2.2. Allogeneic
Chapter 8. Regulatory T-Cell (Tregs) Therapies Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2026-2035
8.1.2. North America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts By Types, 2026-2035
8.1.3. North America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Products, 2026-2035
8.1.3. North America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Source of T-Cells, 2026-2035
8.1.4. North America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by country, 2026-2035
8.2. Europe
8.2.1. Europe Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Therapeutic Area, 2026-2035
8.2.2. Europe Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Types, 2026-2035
8.2.3. Europe Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Products, 2026-2035
8.2.3. Europe Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Source of T-Cells, 2026-2035
8.2.4. Europe Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) by country, 2026-2035
8.3. Asia Pacific
8.3.1. Asia Pacific Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Therapeutic Area, 2026-2035
8.3.2. Asia Pacific Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Types, 2026-2035
8.3.3. Asia Pacific Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Products, 2026-2035
8.3.3. Asia Pacific Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Source of T-Cells, 2026-2035
8.3.4. Asia Pacific Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) by country, 2026-2035
8.4. Latin America
8.4.1. Latin America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Therapeutic Area, 2026-2035
8.4.2. Latin America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Types, 2026-2035
8.4.3. Latin America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Products, 2026-2035
8.4.3. Latin America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Source of T-Cells, 2026-2035
8.4.4. Latin America Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) by country, 2026-2035
8.5. Middle East & Africa
8.5.1. Middle East & Africa Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Therapeutic Area, 2026-2035
8.5.2. Middle East & Africa Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) By Types, 2026-2035
8.5.3. Middle East & Africa Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Products, 2026-2035
8.5.3. Middle East & Africa Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) estimates and forecasts by Source of T-Cells, 2026-2035
8.5.4. Middle East & Africa Regulatory T-Cell (Tregs) Therapies Market revenue (US$ Million) by country, 2026-2035
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
Abata Therapeutics (US),
Cellenkos Inc (US),
Coya Therapeutics (US),
Roche (Switzerland),
Lisata Therapeutics
Sonoma Biotherapeutics (US),
Nektar Therapeutics (US),
Eli Lilly and Company (US),
Baudax Bio
TRACT Therapeutics (US),
VT Bio (South Korea),
Sangamo Therapeutics (TxCell) (US),
TRexBio
Mozart Therapeutics
Pfizer Inc. (US), PolTREG S.A.. (Poland),
Parvus Therapeutics (Canada)
ILTOO Pharma (France),
GentiBio
Tr1X
Quell Therapeutics
AstraZeneca
Kyverna Therapeutics, Inc.
Others
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們